AstraZeneca’s Asthma Treatment Scores European Approval
The European Commission approved AstraZeneca Plc’s (NASDAQ:AZN) Tezspire (tezepelumab) as an add-on maintenance treatment for severe asthma. The approval covers patients…
Zealand Pharma Announces Oral Presentation Of Phase 2 Data For BI 456906 At The 58th Annual Meeting Of The European Association For The Study of Diabetes September 21
Press release – No. 6 / 2022
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
BI 456906
PDS Biotech And National Cancer Institute Identify Optimal Patient Group For Advancing PDS0101-Based Triple Combination Program Targeting Advanced HPV-Positive Cancers
FLORHAM PARK, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and
Alaunos Therapeutics Highlights Data From TCR-T Library Phase 1/2 Trial At The CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference; Data To Be Presented On Friday, September 30
First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusion
Sleeping Beauty TCR-T cell therapy had a manageable safety
VBI Vaccines Announces Presentation Of Physician-Initiated Compassionate Use Data Of 3-Antigen Hepatitis B Vaccine At 2022 International HBV Meeting; Presentation Was Monday, Sept. 19
VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that data from the physician-initiated
Mapi Pharma Announces Top-Line Results From GA Depot Phase III Trial For Relapsing Forms Of Multiple Sclerosis; Says Study Met Primary Endpoint
The study met its primary endpoint showing that GA Depot 40 mg statistically significantly reduced the annualized relapse rate (ARR) by 30.1 percent compared to placebo (p=0.0066)
Novartis To Petition US Supreme Court To Uphold Patent Validity For Multiple Sclerosis Drug, Gilenya
Swiss drug major Novartis AG (NYSE:NVS) plans to petition the U.S. Supreme Court to uphold the validity of the Gilenya (fingolimod) dosing…
FDA Concludes Oversight Shortcomings After Infant Formula Internal Review
The FDA concluded an internal review of agency actions related to the U.S. infant formula supply.
Clene Nanomedicine Presents Updated Long-Term Survival Data From RESCUE-ALS Participants At 2022 AANEM Scientific Conference
Treatment with CNM-Au8 significantly improved long-term survival with approximately a 70% decreased risk of mortality vs. original placebo randomization
Comparable survival benefits were also
Fennec Pharmaceuticals Granted FDA Approval For PEDMARK
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212937